Good randomized controlled trials provide reliable evidence that informs changes in healthcare practice. There is a pressing need to make it easier to do good trials that inform improvements in future care.
Alongside establishing Protas, Martin Landray, Protas’s CEO, has been leading the Good Clinical Trials Collaborative since June 2020 with the aim of driving that change.
Supported by Wellcome, the Bill & Melinda Gates Foundation and the African Academy of Sciences, the aim of the Collaborative is to develop guidance to enable and promote informative, ethical and efficient randomized controlled trials.
The Good Clinical Trials Collaborative has brought together a wide range of individuals and organizations with an interest in and role to play in the design, delivery, analysis and reporting of randomized trials, and in implementing the results. This includes those who fund, regulate, design, deliver, or are responsible for such trials, those who provide audits and quality assurance functions, research organizations, clinicians, participants, ethicists, and lay health advocates. It includes those from a wide variety of sectors (industry, academia, government, charitable, non-governmental organizations, participant and public groups) and settings.
The Collaborative has recently launched the draft guidance for public consultation, which will be running between 4th August to 15th September 2021. They are looking for feedback to help shape the guidance which can be reviewed at goodtrials.org. This work is valuable not only for Protas and its partners but to all who play a role in randomized trials and those who benefit from the results.
“A New National Purpose”: Protas named in report on innovation
Protas was this week named in a new report exploring how the UK should harness innovation in science and technology…
Protas signs strategic partnership with Moderna
Protas is delighted to announce a new strategic partnership with Moderna, the leading biotechnology company pioneering messenger RNA (mRNA). Moderna’s…